Treat sickest hepatitis C patients first, new US guidelines recommendBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5163 (Published 14 August 2014) Cite this as: BMJ 2014;349:g5163
- Michael McCarthy
When access to hepatitis C treatments is limited, patients who are the sickest or who pose the greatest risk of transmitting the virus to others should be treated first, says a new guideline update by the Infectious Diseases Society of America and the American Association for the Study of Liver Diseases, in collaboration with the International Antiviral Society USA.1
With the advent of highly effective but very costly hepatitis C treatments, such as the $1000 (£600; €748) a pill drug sofosbuvir, public and private payers in the United States have been debating how to pay for the treatment …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial